FDA Nicotine Pouch Authorization: 11 New Products in the U.S.
September 2, 2026 | Regulatory Updates
FDA nicotine pouch authorization has expanded the number of nicotine pouch products that can be legally marketed in the United States. On August 21, 2026, the U.S. Food and Drug Administration (FDA) authorized 11 new ZYN ULTRA nicotine pouch products manufactured by Swedish Match USA, Inc. through the Premarket Tobacco Product Application (PMTA) pathway.
The decision represents another significant regulatory development for the U.S. nicotine pouch market, where manufacturers continue to introduce new product formats and nicotine strengths.
FDA Authorizes 11 ZYN ULTRA Products
The latest authorization covers 11 ZYN ULTRA nicotine pouch products. The products include nicotine strengths of 9 mg and 11 mg and are offered in different flavor variants.
The authorized products include ZYN ULTRA Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Smooth, Spearmint, Wintergreen Chill and Wintergreen variants. One Smooth product was authorized at 11 mg, while the other listed products were authorized at 9 mg.
The FDA evaluates tobacco products through a science-based review process before determining whether a product can be marketed legally in the United States.
Regulatory Review Considers Product Characteristics
The FDA’s review considers a range of product-specific factors. These can include nicotine exposure, product design, formulation, ingredients, materials and characteristics that may affect nicotine delivery and absorption.
The agency also considers the potential risks and benefits of a product to the population as a whole. This includes evaluating whether a product may benefit adults who currently use tobacco products while considering potential risks related to non-users and younger populations.
The FDA reported that its evaluation of the newly authorized products included comparisons of harmful and potentially harmful constituents with other oral and smokeless tobacco products.
Total FDA-Authorized Nicotine Pouch Products Reaches 43
Following the latest decision, the FDA reported that it has authorized 43 nicotine pouch products overall.
The agency also said that 23 of those products were authorized through its nicotine pouch pilot program. The pilot program was introduced to improve the efficiency of the PMTA review process for qualifying nicotine pouch applications.
The development provides manufacturers with a clearer indication that regulatory review remains an important part of bringing nicotine pouch products to the U.S. market.
Importance for Nicotine Manufacturers and Suppliers
The latest FDA nicotine pouch authorization also highlights the importance of technical and regulatory preparedness within the nicotine supply chain.
Manufacturers developing nicotine-containing products may need detailed information about raw materials, product specifications, testing procedures and supporting documentation. Consistency between batches can also become important when products are manufactured at commercial scale.
For raw-material suppliers, maintaining clear specifications and technical documentation can help manufacturers evaluate materials during product development and quality-control processes.
However, FDA authorization should not be interpreted as a declaration that nicotine pouches are safe. The FDA states that tobacco products are harmful and potentially addictive, and an authorized product is not the same as an “FDA approved” product.
U.S. Nicotine Pouch Market Remains Closely Regulated
Nicotine pouches continue to attract regulatory attention as the category develops in the United States and other international markets.
For manufacturers, importers, distributors and raw-material suppliers, monitoring regulatory decisions can be important for understanding changing market requirements. Companies entering or expanding in the U.S. market may need to consider product formulation, documentation, testing, labeling and applicable regulatory requirements as part of their planning.
The latest authorization also demonstrates that the regulatory pathway remains active for nicotine pouch manufacturers seeking to introduce additional products.
What Happens Next?
The FDA’s latest decision is likely to keep regulatory compliance at the center of nicotine pouch product development in the United States.
As more manufacturers submit products for regulatory review, the industry will continue to watch FDA decisions involving product composition, nicotine strengths, product characteristics and marketing authorization.
For businesses involved in nicotine manufacturing and supply, staying informed about these developments can help support better product planning and regulatory awareness.
Source: U.S. Food and Drug Administration (FDA), August 21, 2026.
